GlassScriptPhysician profile
Anjali C Dua
NPI 1134182330
$12,137.66
in general payments reported to CMS, 2019-2025
55 companies · $1,351 in 2025
The $1,351 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $818 · 2020: $1,456 · 2021: $3,031 · 2022: $1,757 · 2023: $1,788 · 2024: $1,937 · 2025: $1,351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,990 · Education: $85.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,990.36 |
| Education | $85.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,553.78 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Biohaven Pharmaceuticals, INC. | $1,231.55 | 2021 | |
| Novo Nordisk INC | $1,202.52 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $925.06 | 2019-2025 | Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $803.89 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Astellas Pharma US INC | $728.22 | 2019-2025 | Veozah, Myrbetriq |
| Paratek Pharmaceuticals, INC. | $649.13 | 2020-2025 | Nuzyra |
| Glaxosmithkline, LLC. | $631.75 | 2020-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $367.09 | 2021-2024 | |
| Pfizer INC. | $280.47 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $259.94 | 2019-2024 | |
| Otsuka America Pharmaceutical, INC. | $250.03 | 2019-2025 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $238.83 | 2019-2024 | Livalo |
| Teva Pharmaceuticals USA, INC. | $220.61 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $210.98 | 2019-2025 | Xifaxan |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $207.69 | 2022-2025 | Caplyta |
| Medtronic, INC. | $192.87 | 2021-2024 | Interstim |
| Allergan, INC. | $174.73 | 2019-2021 | |
| Eisai INC. | $172.19 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $151.42 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $150.25 | 2020-2024 | Ofev |
| Janssen Pharmaceuticals, INC | $141.00 | 2022 | |
| Merck Sharp & Dohme LLC | $134.98 | 2019-2025 | Gardasil 9, Capvaxive |
| Amgen INC. | $134.65 | 2021-2025 | Repatha, Otezla, Krystexxa |
| Lundbeck LLC | $129.16 | 2024-2025 | Rexulti |
| Amarin Pharma, INC. | $84.48 | 2020-2022 | |
| Boston Scientific Corporation | $64.44 | 2024-2025 | Watchman Access System |
| Dexcom, INC. | $61.07 | 2024-2025 | Dexcom G6 Transmitter |
| Mannkind Corporation | $59.40 | 2022 | |
| Exact Sciences Corporation | $54.51 | 2024-2025 | Cologuard Collection Kit |
| Horizon Therapeutics Plc | $49.79 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $48.41 | 2022 | |
| Abbott Laboratories | $46.59 | 2023-2025 | Freestyle Libre 3 |
| Acadia Pharmaceuticals INC | $44.29 | 2025 | Nuplazid |
| Qol Medical, LLC | $40.76 | 2023 | Sucraid |
| Corium, LLC | $35.91 | 2023 | Adlarity |
| Cranial Technologies, INC | $35.16 | 2019-2025 | Doc Band |
| Upsher-Smith Laboratories LLC | $34.18 | 2020 | |
| Phadia US INC. | $29.59 | 2022-2023 | Immunocap |
| Saluda Medical Americas, INC. | $27.20 | 2024 | Evoke |
| Optos, INC. | $25.61 | 2020 | |
| Philips North America LLC | $23.65 | 2024 | (Ck7) Extended Holter |
| Idorsia Pharmaceuticals US INC | $23.05 | 2022 | |
| Echosens North America, INC. | $21.92 | 2025 | Fibroscan |
| Inspire Medical Systems, INC. | $20.08 | 2025 | Inspire |
| Neurocrine Biosciences, INC. | $19.48 | 2023 | Ingrezza |
| Circassia INC. | $18.42 | 2019 | |
| Genentech USA, INC. | $17.86 | 2019 | |
| Medtronic USA, INC. | $17.06 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.63 | 2022 | |
| Sanofi Pasteur INC. | $16.49 | 2019 | |
| Linus Health, INC. | $15.96 | 2023 | |
| Melinta Therapeutics, LLC | $15.60 | 2019 | |
| Metacel Pharmaceuticals LLC | $14.64 | 2022-2023 | Ozobax |
| Vivus LLC | $12.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anjali Dua listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.